Tepotinib (EMD1214063), developed by Merck, has more than 1000-fold selectivity for c-Met.55 Clinical trials of tepotinib (NCT04647838 and NCT03940703) also showed significant effectiveness in the treatment of cancer patients harboring MET mutations and in combination therapy with EGFR TKIs.56 It has been approved by the Ministry of Health, Labour and Welfare (MHLW) of Japan for the treatment of unresectable, advanced, or recurrent NSCLC in patients with skipping mutations in MET exon 14.57 This evidence concerns the gene MET and non-small cell lung carcinoma.